The beat drives near-term bullish momentum, but the guidance cut due to the Emalex acquisition introduces uncertainty. Watch for details on Emalex integration and biosimilar approvals (PONLIMSI, Xolair biosimilar) over the next few quarters.
Price Chart
Executive Summary
Teva reported Q1 2026 non-GAAP EPS of $0.53, beating consensus of $0.46 by 15%, and revenue of $3.98B, beating $3.79B by 5%. Innovative products (AUSTEDO, AJOVY, UZEDY) grew 41% YoY, offsetting generic erosion. However, 2026 guidance was effectively lowered from prior stand-alone due to the Emalex acquisition, with non-GAAP diluted EPS now guided at $1.91-$2.11 vs. prior $2.57-$2.77.
Key Financial Metrics
Key Facts
- Non-GAAP diluted EPS $0.53 vs. consensus $0.46 (beat 15.2%)
- Revenue $3.98B vs. consensus $3.79B (beat 5.1%)
- Revenue growth +2% USD (-3% local currency); YoY revenue up $91M
- Innovative brands (AUSTEDO, AJOVY, UZEDY) grew 41% YoY in local currency
- Generics revenue down 16% in local currency, driven by lenalidomide competition
- 2026 guidance maintained but lowered from stand-alone: non-GAAP EPS $1.91-$2.11 (stand-alone $2.57-$2.77) due to Emalex acquisition
- Board authorized future share repurchase program (not yet implemented)
- Free cash flow of $188M; operating cash flow negative $40M due to working capital
Financial Impact
Earnings beat of $0.07/share vs consensus; revenue beat of ~$192M; guidance cut of ~$0.66/share from prior stand-alone
Risk Factors
- Accelerating generic competition for lenalidomide capsules
- Execution risk on Emalex integration and pipeline milestones
- High debt ($16.6B) and financial leverage (67%)
- Foreign exchange volatility (positive impact in Q1 but uncertain going forward)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3283605 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 22d ago | Press Release | $36.35 $39.19 | ▲ +7.81% | ▲ +8.31% | $39.29 (+8.09%) |
Sep 8, 2026 24d ago | 424B5 | $36.76 $39.25 | ▲ +6.77% | ▲ +7.89% | $39.29 (+6.88%) |
Sep 2, 2026 4w ago | Court Ruling | $37.49 $36.35 | ▼ −3.04% | ▼ −2.08% | $39.29 (+4.80%) |
Aug 28, 2026 5w ago | Press Release | $36.44 $36.36 | ▼ −0.22% | ▼ −0.33% | $39.29 (+7.82%) |
Aug 25, 2026 5w ago | Court Ruling | $38.10 $36.20 | ▼ −4.99% | ▼ −4.46% | $39.29 (+3.12%) |
Aug 25, 2026 5w ago | Insider Cluster | $38.10 $36.20 | ▼ −4.99% | ▼ −4.46% | $39.29 (+3.12%) |
Aug 10, 2026 7w ago | Insider Cluster | $36.14 $36.46 | ▲ +0.89% | ▲ +0.93% | $39.29 (+8.72%) |
Aug 5, 2026 8w ago | Insider Cluster | $34.81 $36.45 | ▲ +4.70% | ▲ +3.49% | $39.29 (+12.87%) |
Jul 31, 2026 9w ago | Court Ruling | $35.01 $35.36 | ▲ +1.00% | ▼ −2.51% | $39.29 (+12.23%) |
Jul 29, 2026 9w ago | 8-K | $34.71 $34.72 | ▲ +0.03% | ▼ −5.50% | $39.29 (+13.20%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access